Mardepodect

• Description :

  Mardepodect (PF-2545920) is a potent, orally active and selective PDE10A inhibitor with an IC50 of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect can cross the blood-brain barrier[1][2].

• Product Name Alternative :

  PF-2545920

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/PF-2545920.html

• Purity :

  98.81

• Solubility :

  DMSO : ≥ 45 mg/mL

• Smiles :

  CN(N=C1C2=CC=C(OCC3=NC4=CC=CC=C4C=C3)C=C2)C=C1C5=CC=NC=C5

• Molecular Formula :

  C25H20N4O

• Molecular Weight :

  392.45

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]Verhoest PR, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4- (1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl) -phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem, 2009, 52 (16), 5188-5196.|[2]Grauer SM, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther, 2009, 331 (2), 574-590.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  PDE10

• Citation 01 :

  BioRxiv. 2025 March 17.|Toxicol Appl Pharmacol. 2024 May:486:116945.|Patent. US20230111925A1.

• CAS Number :

  [898562-94-2]